No-Spa Forte tablets 80 mg blister 24 pcs

For therapeutic purposes in:

• smooth muscle spasms associated with biliary tract diseases: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papilloma;
• smooth muscle spasms in diseases of the urinary tract: nephrolithiasis, urethrolithiasis, pyelitis, cystitis, bladder tenesmus.

As an adjunctive treatment for:

• spasms of smooth muscles of the gastrointestinal tract: gastric and duodenal ulcers, gastritis, cardio- and / or pylorospasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome, accompanied by flatulence;
• tension headache;
• gynecological diseases (dysmenorrhea).

Hypersensitivity to drotaverine or to any component of the drug. Severe hepatic, renal or heart failure (low cardiac output syndrome). Lactase deficiency, galactosemia or glucose-galactose malabsorption syndrome. Breastfeeding.

Children under 12 years old.

Antispasmodics affect smooth muscles and eliminate pain caused by spasm. The antispasmodic drotaverine is used in gastroenterology, therapy, urology and gynecology in many countries of the world.

• Gastroenterology. In this area, the drug is prescribed for spastic pain accompanying biliary tract pathology – cholelithiasis, acute or chronic cholecystitis, cholangitis, etc.
• Urology. Inflammatory processes in the urinary organs (cystitis, pyelitis) can also lead to spasms, so the use of drotaverine in these diseases is fully justified.
• Tension headaches. Drotaverine

The favorable safety profile has been confirmed by numerous clinical studies.

Adults: The usual average dose is 120-240 mg per day in 2-3 divided doses.

Children over 12 years of age: if necessary, as prescribed by a doctor, the maximum daily dose is 160 mg (1/2 tablet 2-4 times a day).

The duration of treatment is determined by the doctor individually.

The No-Spa forte tablet can be divided in half.

Children

The use of the drug in the treatment of children under 12 years of age is contraindicated.

Use during pregnancy or breastfeeding

Pregnancy: Results of retrospective clinical studies have shown that oral administration of the drug did not cause any signs of any direct or indirect effect on pregnancy. However, caution should be exercised when prescribing the drug to pregnant women.

Breastfeeding. Due to the lack of data, the use of the drug during breastfeeding is not recommended.

Active ingredient: drotaverine; 1 tablet contains drotaverine hydrochloride 80 mg.

Excipients: magnesium stearate, talc, povidone, corn starch, lactose.

Keep out of reach of children. Store in the original packaging at a temperature below 25 °C.